PAVmed Inc. (PAVM) Financial Statements (2024 and earlier)

Company Profile

Business Address 360 MADISON AVENUE
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,63926,40837,16349,28039,74456,785
Cash and cash equivalents19,63926,40837,16349,28039,74456,785
Receivables613641271731
Inventory, net of allowances, customer advances and progress billings278     
Inventory278     
Prepaid expense848479799233300453
Other undisclosed current assets3,6725,5385,1244,3013,8654,710
Total current assets:24,49832,46143,12753,84143,92661,979
Noncurrent Assets
Operating lease, right-of-use asset4,2674,6635,0145,1713,0373,079
Property, plant and equipment1,7831,8202,0282,2552,4512,374
Intangible assets, net (including goodwill)1,4241,9292,4352,9403,4453,950
Intangible assets, net (excluding goodwill)1,4241,9292,4352,9403,4453,950
Other noncurrent assets1,1471,1471,0791,0791,1211,083
Total noncurrent assets:8,6219,55910,55611,44510,05410,486
TOTAL ASSETS:33,11942,02053,68365,28653,98072,465
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,6267,6506,1084,9823,7055,384
Accounts payable1,7862,1651,1621,2582,7042,454
Accrued liabilities6,6265,4854,9463,7243,7052,930
Other undisclosed accounts payable and accrued liabilities (1,786)   (2,704) 
Debt44,20044,99042,99044,30033,65035,500
Derivative instruments and hedges, liabilities  291260   
Other undisclosed current liabilities3,3511,5741,4271,2643,8451,027
Total current liabilities:54,17754,50550,78550,54641,20041,911
Noncurrent Liabilities
Long-term debt and lease obligation:      1,998
Liabilities, other than long-term debt2,9603,3433,7283,9361,846 
Operating lease, liability2,9603,3433,7283,9361,8461,998
Other undisclosed noncurrent liabilities      (1,998)
Total noncurrent liabilities:2,9603,3433,7283,9361,8461,998
Total liabilities:57,13757,84854,51354,48243,04643,909
Equity
Equity, attributable to parent(53,831)(43,259)(31,512)(22,057)(9,681)8,948
Preferred stock2,9932,9162,8412,7672,6952,624
Common stock91201091019592
Treasury stock, value     (408)(408)
Additional paid in capital237,600232,234226,321221,247216,106214,278
Accumulated deficit(294,433)(278,529)(260,783)(246,172)(228,169)(207,638)
Equity, attributable to noncontrolling interest29,81327,43130,68232,86120,61519,608
Total equity:(24,018)(15,828)(830)10,80410,93428,556
TOTAL LIABILITIES AND EQUITY:33,11942,02053,68365,28653,98072,465

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues1,09779116644618876
Net investment income97124163121  
Cost of revenue(1,611)(1,779)(1,685)(1,346)(1,618)(1,626)
Gross profit:(514)(988)(1,519)(900)(1,430)(1,550)
Operating expenses(15,821)(14,540)(14,965)(19,501)(22,998)(21,763)
Other undisclosed operating income (loss)(48)   (76) 
Operating loss:(16,383)(15,528)(16,484)(20,401)(24,504)(23,313)
Nonoperating expense(1,025)(6,222)(1,408)(1,813)(68)(6,619)
Other nonoperating expense (1,025)(6,222)(1,408)(1,813)(68)(6,619)
Interest and debt expense(750)(1,764)(743)(525)(311)5,100
Loss from continuing operations before equity method investments, income taxes:(18,158)(23,514)(18,635)(22,739)(24,883)(24,832)
Other undisclosed income (loss) from continuing operations before income taxes7501,764743525311(5,100)
Loss from continuing operations:(17,408)(21,750)(17,892)(22,214)(24,572)(29,932)
Loss before gain (loss) on sale of properties:(29,932)
Net loss:(17,408)(21,750)(17,892)(22,214)(24,572)(29,932)
Net income attributable to noncontrolling interest3,3724,0793,3554,2834,1123,806
Net loss attributable to parent:(14,036)(17,671)(14,537)(17,931)(20,460)(26,126)
Preferred stock dividends and other adjustments(78)(77)    
Other undisclosed net loss available to common stockholders, basic(1,791) (75)(74)(72)(71)
Net loss available to common stockholders, diluted:(15,905)(17,748)(14,612)(18,005)(20,532)(26,197)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(17,408)(21,750)(17,892)(22,214)(24,572)(29,932)
Comprehensive loss:(17,408)(21,750)(17,892)(22,214)(24,572)(29,932)
Comprehensive income, net of tax, attributable to noncontrolling interest3,3724,0793,3554,2834,1123,806
Comprehensive loss, net of tax, attributable to parent:(14,036)(17,671)(14,537)(17,931)(20,460)(26,126)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: